I'll research this entity before writing.
Pharmacia Enterprises S.A. — Luxembourg-domiciled corporate and intellectual-property holding company of the Pharmacia group, registered at 6, Circuit de la Foire Internationale, L-1347 Luxembourg. It was originally incorporated as Pharmacia & Upjohn S.A. (earlier Upjohn Enterprises S.A.) and renamed Pharmacia Enterprises S.A. around 2001. It is not an independent operating business: its purpose was to hold pharmaceutical patents, trademarks and regional subsidiaries on behalf of Pharmacia Corporation (then headquartered in Peapack, New Jersey, and NYSE-listed). Pharmacia Corporation was formed in April 2000 through the merger of Pharmacia & Upjohn and Monsanto, whose pharmaceutical roots trace to Pharmacia AB (Sweden, 1911) and Upjohn (1886). On April 16, 2003, Pfizer Inc. completed its acquisition of Pharmacia Corporation, making Pharmacia Enterprises S.A. an indirect Pfizer subsidiary; the Luxembourg entity was subsequently renamed Pfizer Enterprises Sàrl. Former branch registrations in Lithuania and Slovakia have been liquidated. Because Pharmacia was absorbed into Pfizer, no separate revenue or headcount figure specific to this entity is publicly reported.
Operations. Pharmacia Enterprises S.A. has no distinct products of its own; the group's operating business was prescription pharmaceuticals (for example Celebrex, Xalatan, Camptosar and Detrol), plus consumer health, animal health and diagnostics lines. The Luxembourg entity functioned as a title-holder and trademark owner — trademark records show it holding marks such as Depo-Provera, Solu-Medrol, Solu-Cortef and Prepidil.
Litigation posture. A conventional operating-company patent owner, not an NPE. The tracked data shows 1 case as plaintiff and 0 as defendant, consistent with a brand pharmaceutical company enforcing Orange Book patents through Hatch-Waxman litigation. It asserted jointly-owned patents rather than an acquired assertion portfolio; the venue was the District of New Jersey, the home district for the group, not a plaintiff-friendly NPE venue such as the Eastern District of Texas.
Notable case. Pharmacia Corporation, Pharmacia AB, Pharmacia Enterprises S.A. and Pharmacia & Upjohn Company v. Par Pharmaceutical, Inc. (D.N.J., filed Dec. 21, 2001; Fed. Cir. Nos. 04-1478/-1496, 417 F.3d 1369, Aug. 10, 2005). The suit responded to Par's ANDA No. 76-218 for generic Xalatan (latanoprost, a glaucoma treatment) and asserted U.S. Patents 5,296,504 and 5,422,368, co-owned by the Pharmacia plaintiffs and licensed from Columbia University. The Federal Circuit affirmed that the '368 patent was unenforceable for inequitable conduct during prosecution while the '504 patent remained enforceable.